Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900559 | 0.81 | BRAF (0.59) | BRAFPOLBKDM4EUSP2IGF1R | |
| SCHEMBL19219203 | 0.80 | CDK9 (0.57) | KDM4EUSP2ALDH1A1MAPTCDK2 | |
| SCHEMBL6895308 | 0.77 | IGF1R (0.58) | BRAFIGF1R | |
| SCHEMBL4332018 | 0.77 | PIK3CG (0.58) | BRAFFYN | |
| SCHEMBL7117471 | 0.74 | BRAF (0.56) | BRAFKDM4EALDH1A1IGF1RCDK2 | |
| SCHEMBL6893744 | 0.74 | BRAF (0.53) | BRAFTGFBR1IGF1R | |
| SCHEMBL6897653 | 0.73 | IGF1R (0.63) | BRAFTGFBR1IGF1RRPS6KA2 | |
| SCHEMBL1122460 | 0.72 | BRAF (1.00) | BRAF | |
| SCHEMBL6901887 | 0.72 | BRAF (0.54) | BRAFPOLBKDM4EUSP2IGF1R | |
| SCHEMBL1116441 | 0.71 | IGF1R (0.76) | BRAFALDH1A1MAPTTGFBR1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004510707-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | claimed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | BRAF 4006/4885POLB 4405/4885KDM4E 3069/4885 |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | BRAF 4006/4885POLB 4405/4885KDM4E 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.